Indications

Melanoma (see Melanoma, Melanoma)

• Clinical Efficacy
  • xxx

Non-Small Cell Lung Cancer (see Lung Cancer, Lung Cancer)

• Clinical Efficacy
  • POPLAR (Phase 2) Trial of Atezolizumab vs Docetaxel for Previously-Treated Non-Small Cell Lung Cancer (Lancet, 2016) [MEDLINE]: atezolizumab significantly improved survival compared with docetaxel
    • Improvement correlated with PD-L1 immunohistochemistry expression on tumor cells and tumor-infiltrating immune cells, suggesting that PD-L1 expression is predictive of atezolizumab benefit
    • Atezolizumab was well tolerated, with a safety profile distinct from chemotherapy

---

Pharmacology

• Atezolizumab is a Programmed Cell Death Protein 1 (PD-1) Checkpoint Inhibitor (see Programmed Cell Death Protein 1 Checkpoint Inhibitors, Programmed Cell Death Protein 1 Checkpoint Inhibitors): binds to PD-L1, inhibiting the interaction of PD-L1 with PD-1 and B7.1
  • PD-1 is a Key Immune-Checkpoint Receptor Expressed by Activated T-Cells: PD-1 mediates immunosuppression
  • T-Cells Encounter the Immunosuppressive PD-1 Ligands, PD-L1 (B7-H1) and PD- L2 (B7-DC), Which are Expressed by Tumor Cells and/or Stromal Cells

Metabolism

• xxxx

---

Administration

• xxxx

Dose Adjustment

• Hepatic:
• Renal:

---

Adverse Effects

Other Adverse Effects

• xxx
• xxx
• xxx

---

References

• Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016 Mar 9. pii: S0140-6736(16)00587-0. doi: 10.1016/S0140-6736(16)00587-0 [MEDLINE]
• PD-L1 in non-small-cell lung cancer: the third target for immunotherapy. Lancet. 2016 Mar 10. pii: S0140-6736(16)00700-5. doi: 10.1016/S0140-6736(16)00700-5 [MEDLINE]